← boardnext 2028-07
SMNR
Semnur Pharmaceuticals, Inc.distress 6/10 · elevated risk$0.74+16%today-97% from 52w high
Lead: Lumbosacral Radicular Pain
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+0%
Price & events
-91.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+15.6%
1D
+3.5%
1W
+92.6%
1M
-85.2%
3M
-91.6%
6M
—
1Y
—
2Y
—
5Y
-96.3%
All
Overview
- Market Cap
- $170.35M
- Volume
- 8.32K
- 52 Week Range
- $0.35 – $23.00
- Total Shares
- 230.21M
- Float Shares
- 48.69M
- % Held by Insiders
- 84.28%
- % Held by Institutions
- 0.00%
- RVOL
- 0.16x
- Beta
- 0.15
Pipeline stages · 1 programs
SP-102, Dexamethasone Sodium Phosphate 10 MG/ML
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-07 Estimated 50% readout ~2028-09-14 | Phase 3 | SP-102, Dexamethasone Sodium Phosphate 10 MG/ML | Lumbosacral Radicular Pain | — | not yet recruiting |
Catalyst news & presentations · 1
- 2025-05-09enrollment delayExtended deadline to complete business combination from May 11, 2025 to June 11, 2025 via $874.78 deposit.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 230,209,142 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Lumbosacral Radicular Pain
- none identified
Recent news
- 2026-07-22Enterprise value to EBITDA forward of Semnur Pharmaceuticals Inc. – OTC:SMNRW - TradingView
- 2026-07-22Semnur Pharmaceuticals signs binding term sheet for $100M equity investment from iHolding Group - MSN
- 2026-07-07Semnur Pharmaceuticals Secures $100 Million Equity Investment Term Sheet From iHolding at $10/Share - TradingView
- 2026-07-07Semnur Pharmaceuticals signs term sheet for $100M investment By Investing.com - Investing.com Nigeria
- 2026-07-07Semnur Pharmaceuticals, Inc. ('Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, 'Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP - The Manila Times
- 2026-07-07Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP - Yahoo Finance
- 2026-06-26Form 13D/A Semnur Pharmaceuticals For: 26 June By Investing.com - Investing.com Canada
- 2026-06-17Semnur Pharmaceuticals, Inc.(OTCPK: SMNR) dropped from S&P TMI Index - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.